Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07600177 · ClinicalTrials.gov registry record · Phase 4
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
A Phase 4 study, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT07600177 is a Phase 4 study that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 40 participants.
The verdict
NCT07600177, a Phase 4 study, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Interventions
- DRUG Aficamten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-05-05 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07600177
The ClinicalTrials.gov registry entry for NCT07600177 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aficamten is the first listed.
NCT07600177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07600177 about?
NCT07600177 is a clinical study titled "Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy". This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
What is the current status of trial NCT07600177?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2026-05-05. Estimated completion is 2027-03-15.
What interventions are being tested in trial NCT07600177?
The interventions under investigation include: Aficamten (DRUG).
Who is sponsoring clinical trial NCT07600177?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.